Latest Healthcare News

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

Aroa Biosurgery posted a breakout FY26, beating revenue and EBITDA guidance with a 54% surge in Myriad sales. The company plans significant investments in FY27 to accelerate growth and capitalise on new market opportunities.

Ryman Healthcare reported a substantial reduction in net loss for FY26 alongside its first positive free cash flow in over a decade, driven by operational improvements, refinancing, and land divestments.

Fisher & Paykel Healthcare posted a 14% revenue increase to NZ$2.31 billion and a 24% rise in net profit to NZ$468.5 million for FY2026, driven by strong hospital product sales and ongoing innovation.

Little Green Pharma has secured Federal Court approval for its full acquisition of Cannatrek, marking a key milestone in expanding its global medicinal cannabis footprint. The scheme became effective on 25 May 2026, with implementation set for 1 June.

IMEXHS has landed a significant public tender in Mexico, deploying its AI-powered Aquila+ radiology platform across 20 hospitals, adding $384,000 in new annual recurring revenue and advancing its Latin American expansion.

Anteris Technologies Global Corp. has initiated an at-the-market equity offering to raise up to US$250 million, aiming to accelerate development of its DurAVR transcatheter heart valve and support general corporate needs.

Alcidion has landed a $35 million, seven-year contract to deploy its Miya Precision Electronic Patient Record platform at University Hospitals Sussex, marking a significant expansion in the UK healthcare IT market.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

Radius Residential Care has syndicated its bank debt, boosting facility limits by NZD 30 million and cutting financing costs by 65 basis points to support its growth plans, including a new care home acquisition and development projects.

TruScreen Group has secured NZ$1.82 million through an oversubscribed placement, underscoring investor confidence amid its global cervical screening expansion. The company also announced a renounceable rights issue and attaching options, both subject to shareholder approval.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.